The impact of our research
Tourette syndrome affects up to one in 100 people, with symptoms usually starting in childhood. Treatment often involves anti-psychotic medication, which can lead to unwanted side effects.
QIMR Berghofer researchers have studied the entire set of DNA (genome) of a large group of people with Tourette syndrome (TS). The goal is to understand the overlap between genes that increase the risk of TS and how these influence specific brain structures.
Our researchers have published the first robust clinical study proving that medicinal cannabis effectively treats the debilitating effects of TS.
We’re exploring the impact of iron supplements to see if this reduces the severity of tics.
About tourette syndrome
Tourette syndrome (TS) is a neurodevelopmental disorder characterised by multiple and repetitive motor and vocal tics. Symptoms need to persist for more than one year to receive a TS diagnosis.
It’s thought that genetic and environmental factors contribute to the development of Tourette syndrome.
An estimated one in 100 people is affected by Tourette syndrome, with symptoms usually starting in childhood.
Tourette syndrome is characterised by sudden, rapid movements or vocalisations, called tics. These are often involuntary. Although most people with Tourette syndrome can suppress their tics for a time, they often report that this causes discomfort.
Tics can be classified as simple – such as eye blinking or throat clearing – or more complex. Complex tics can take longer to perform and may include a combination of simple tics. Examples include:
- repeating sounds, words or phrases;
- using socially inappropriate words or obscene gestures;
- touching other people and things;
- hitting oneself.
While there are pharmacological treatments for Tourette syndrome, they usually involve anti-psychotic medication. This can cause adverse side effects, especially in children.